Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:approves |
multiple countries
|
| gptkbp:average_temperature |
-80 to -60 degrees Celsius
|
| gptkbp:clinical_trial |
gptkb:Argentina
gptkb:Brazil gptkb:Germany gptkb:Turkey gptkb:United_States Phase 3 |
| gptkbp:community_health |
reduced hospitalization rates
contributed to herd immunity reduced severe disease |
| gptkbp:developed_by |
gptkb:Pfizer
gptkb:Bio_NTech |
| gptkbp:dosage_form |
after initial series
|
| gptkbp:dosing_interval |
21 days apart
|
| gptkbp:emergency_services |
granted by FDA
|
| gptkbp:first_dose |
two doses required
|
| https://www.w3.org/2000/01/rdf-schema#label |
BNT162b21
|
| gptkbp:is_effective_against |
95% effective
|
| gptkbp:is_vulnerable_to |
global distribution
ongoing studies collaborative efforts preventive vaccine campaigns conducted available in pharmacies against variants accelerated due to pandemic monitored by health authorities reduced transmission available in hospitals based on clinical trial data coordinated by governments CDC guidelines available in clinics full approval in some regions started in December 2020 studied in real-world settings |
| gptkbp:manufacturer |
gptkb:Pfizer-Bio_NTech
|
| gptkbp:market |
ongoing
|
| gptkbp:marketed_as |
gptkb:Comirnaty
|
| gptkbp:mechanism_of_action |
induces immune response
|
| gptkbp:route_of_administration |
intramuscular
|
| gptkbp:side_effect |
fatigue
headache muscle pain fever joint pain chills |
| gptkbp:supply_chain |
cold chain required
|
| gptkbp:targets |
gptkb:SARS-Co_V-2_spike_protein
gptkb:COVID-19 |
| gptkbp:type |
gptkb:vaccine
|
| gptkbp:vaccine_information |
provided by health organizations
|
| gptkbp:whoapproval |
listed for emergency use
|
| gptkbp:bfsParent |
gptkb:Bio_NTech
|
| gptkbp:bfsLayer |
5
|